File S1 - PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

Supporting information. Figure S1 Representative PIK3CA mutations by direct sequencing are shown for exon 9(A) and exon 20(B). Figure S2 Representative high expression of PI3K P110α, p-Akt, m TOR and low expression of PTEN protein in lung SCC; original amplification, ×200 (A); Representative high expression of PI3K, p-Akt, m TOR and PTEN protein in lung AD; original amplification, ×200 (B); Representative cell nuclei having normal(C), gain (D), and amplified (E) PIK3CA signals (red) and two centromeric signals (green). Figure S3 Overall survival curves for patients with or without adjuvant chemotherapy (A); Recurrence-free survival curves for patients with or without adjuvant chemotherapy (B). Figure S4 Overall survival curves for patients with or without PIK3CA amplification (A); Recurrence-free survival curves for patients with or without PIK3CA amplification (B). Table S1 Comparison of PIK3CA helical(exon9) and kinase(exon20) domain mutation. Table S2 ALK rearrangement in 1117 NSCLC patients. Table S3 Correlations between PIK3CA mutations and other gene alterations in lung adenocarcinoma. Table S4 Correlations between PIK3CA mutations and other gene alterations in lung squamous cell carcinoma. Table S5 Comparison of patients with single PIK3CA mutation to those with PIK3CA and other oncogene mutation. Table S6 Histopathological subtype in 785 PIK3CA wildtype and 22 PIK3CA mutant patients with lung adenocarcinoma. Table S7 Comparison of histopathological subtype between lung adenocarcinoma patients only with PIK3CA mutation and those co-exited with EGFR/KRAS mutation. Table S8 Associations of PI3K p110 α, p-Akt, mTOR, PTEN expression and PIK3CA amplification with clinicopathologic characteristics of 34 patients in PIK3CA mutant group. Table S9 Associations of PI3K p110 α, p-Akt, mTOR, PTEN expression and PIK3CA amplification with clinicopathologic characteristics of 108 patients in PIK3CA wild-type group. Table S10 Associations of PI3K p110α, p-Akt, mTOR, PTEN expression and PIK3CA amplification with clinicopathologic characteristics. (PDF)